Menu
Search
|

Menu

Close
X

Motif Bio PLC MTFB.OQ (NASDAQ Stock Exchange Capital Market)

10.08 USD
-- (--)
As of Feb 22
chart
Previous Close 10.08
Open --
Volume --
3m Avg Volume 732
Today’s High --
Today’s Low --
52 Week High 13.70
52 Week Low 5.84
Shares Outstanding (mil) 263.13
Market Capitalization (mil) 118.90
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.00 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-0.149
FY16
-0.341
FY15
-0.127
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
28.10
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-528.64
14.43
Return on Equity (TTM)
vs sector
-541.44
16.13

EXECUTIVE LEADERSHIP

Richard Morgan
Non-Executive Chairman of the Board, Since
Salary: --
Bonus: --
Graham Lumsden
Chief Executive Officer, Executive Director, Since
Salary: --
Bonus: --
Jonathan Gold
Interim Chief Financial Officer, Non-Executive Director, Since 2018
Salary: --
Bonus: --
Rajesh Shukla
Vice President - Clinical Operations, Since 2016
Salary: --
Bonus: --
Robert Bertoldi
Executive Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

One Tudor Street
LONDON     EC4Y 0AH

Phone:

Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP). Iclaprim exhibits potent activity against Gram-positive clinical isolates of various genera of staphylococci. It intends to build a portfolio of antibiotics by licensing drug candidates from organizations specializing in antibacterial research, and is pursuing programs in various stages of development.

SPONSORED STORIES